|
Hodgkin Disease
|
0.550 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
To determine the incidence of REL amplification and possible clinical or histologic association with DLLC, a panel of 111 tumor DNAs from DLLC specimens was screened for REL amplification by Southern blot analysis.
|
8547649 |
1996 |
|
Diffuse Large B-Cell Lymphoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma.
|
8547649 |
1996 |
|
Congenital chromosomal disease
|
0.020 |
Biomarker
|
group |
BEFREE |
As a group, the tumors with REL amplification demonstrated an increased frequency of chromosomal aberrations previously associated with tumor progression, suggesting an oncogenic effect of amplified REL in B-lymphoid cells that already contained a transforming genetic lesion.
|
8547649 |
1996 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
As a group, the tumors with REL amplification demonstrated an increased frequency of chromosomal aberrations previously associated with tumor progression, suggesting an oncogenic effect of amplified REL in B-lymphoid cells that already contained a transforming genetic lesion.
|
8547649 |
1996 |
|
Adult Diffuse Large Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma.
|
8547649 |
1996 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma.
|
8547649 |
1996 |
|
extranodal lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, REL amplification is a frequent event in DLLC, and probably constitutes a progression-associated marker of primary extranodal lymphomas.
|
8547649 |
1996 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene.
|
8608249 |
1996 |
|
Juvenile Myelomonocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that the aberrant, constitutive GM-CSF gene activation in JMML is maintained by TNFalpha-mediated activation of NF-kappaB/Rel proteins.
|
9185524 |
1997 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To study the possible involvement of NF-kappaB/Rel genes in the development of pediatric acute lymphoblastic leukemia (ALL), DNA samples from 140 patients were examined by Southern blot analysis.
|
9264393 |
1997 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Twenty primary central nervous system lymphomas (PCNSL) from immunocompetent patients (nineteen B-cell lymphomas and one T-cell lymphoma) were investigated for genetic alterations and/or expression of the genes BCL2, CCND1, CDK4, CDKN1A, CDKN2A, MDM2, MYC, RB1, REL, and TP53.
|
9546285 |
1998 |
|
T-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Twenty primary central nervous system lymphomas (PCNSL) from immunocompetent patients (nineteen B-cell lymphomas and one T-cell lymphoma) were investigated for genetic alterations and/or expression of the genes BCL2, CCND1, CDK4, CDKN1A, CDKN2A, MDM2, MYC, RB1, REL, and TP53.
|
9546285 |
1998 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesize that NF-kappaB/Rel proteins may represent the point of convergence of several signalling pathways relevant for initiating or accelerating the process of neuronal dysfunction and degeneration in many neurological diseases, including Parkinson's disease, Alzheimer's disease, CNS viral infections, and possibly others.
|
9920279 |
1999 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The implication of NF-kappaB/Rel proteins and their IkappaB regulatory subunits in the control of cellular growth and oncogenesis, was suggested by the induction of fatal lymphomas in birds by the v-rel oncoprotein, and the rearrangement and amplification of several genes encoding the NF-kappaB/Rel/IkappaB signal transduction factors in human malignancies, primarily of lymphoid origin.
|
10340377 |
1999 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells.
|
10521406 |
1999 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells.
|
10521406 |
1999 |
|
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells.
|
10521406 |
1999 |
|
Lupus Erythematosus, Systemic
|
0.030 |
Biomarker
|
disease |
BEFREE |
Significantly increased levels of c-rel mRNA were found (1) in PBMC from SLE patients (n = 48; p<0.0000001), even during inactive disease (n = 11; p<0.001), compared to controls (n = 54), and (2) in T cells isolated from a subgroup of these patients (n = 11; p<0.00002) and controls (n = 12). c-Rel protein was found increased in the cytosol but not in the nucleus of PBMC of patients with SLE (n = 12; p<0.02) compared to controls (n = 12).
|
10648027 |
2000 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
There is increasing evidence for an involvement of NF-kappaB/rel proteins in lymphomagenesis and resistance of lymphoid tumors to the induction of apoptosis.
|
10830747 |
2000 |
|
Myeloproliferative disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders.
|
10830747 |
2000 |
|
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
There is increasing evidence for an involvement of NF-kappaB/rel proteins in lymphomagenesis and resistance of lymphoid tumors to the induction of apoptosis.
|
10830747 |
2000 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
All CVI-NHL scored negative for genetic lesions of BCL-2, p53, c-MYC, REL as well as for viral infection by EBV and HHV-8.
|
10923927 |
2000 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
All CVI-NHL scored negative for genetic lesions of BCL-2, p53, c-MYC, REL as well as for viral infection by EBV and HHV-8.
|
10923927 |
2000 |
|
Lymphoma, Follicular
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study shows the usefulness of coupling CGH, for detecting recurring abnormalities, with the real-time PCR technique for rapid gene dosage quantification and confirms that the REL gene is a potential candidate in the pathogenesis of a particular subset of follicular lymphomas.
|
11122110 |
2000 |